ONC
BeOne Medicines Ltd.
Pharmaceutical PreparationsNasdaqLarge accelerated filer
Total Trades
42
Buys
0
Sells
32
Largest Trade
N/A
Insiders
8
Institutional Funds
236
Inst. Value
$1M+
Activist Filings
13
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Lee Chan Henry | SVP, General Counsel | EXERCISE | $100K–$500K | 2K | $191.40 | Feb 6, 2026 |
| Lee Chan Henry | SVP, General Counsel | SELL | $500K+ | 2K | $349.52 | Feb 6, 2026 |
| Lee Chan Henry | SVP, General Counsel | SELL | $100K–$500K | 664 | $331.76 | Jan 9, 2026 |
| Lee Chan Henry | SVP, General Counsel | EXERCISE | $100K–$500K | 664 | $191.56 | Jan 9, 2026 |
| OYLER JOHN | CEO | SELL | $1M+ | 100K | $306.59 | Dec 17, 2025 |
| Lee Chan Henry | SVP, General Counsel | EXERCISE | $100K–$500K | 664 | $191.56 | Dec 12, 2025 |
| Lee Chan Henry | SVP, General Counsel | SELL | $100K–$500K | 664 | $321.64 | Dec 12, 2025 |
| Sanders Corazon (Corsee) D. | Director | SELL | $500K+ | 3K | $340.90 | Dec 1, 2025 |
| Sanders Corazon (Corsee) D. | Director | EXERCISE | $100K–$500K | 3K | $159.03 | Dec 1, 2025 |
| Wu Xiaobin | President and COO | SELL | $1M+ | 4K | $380.43 | Nov 19, 2025 |
| Wu Xiaobin | President and COO | SELL | $1M+ | 16K | $365.22 | Nov 14, 2025 |
| Lee Chan Henry | SVP, General Counsel | EXERCISE | $100K–$500K | 996 | $191.47 | Nov 14, 2025 |
| Lee Chan Henry | SVP, General Counsel | SELL | $100K–$500K | 996 | $349.17 | Nov 14, 2025 |
| OYLER JOHN | CEO | SELL | $1M+ | 28K | $325.71 | Sep 18, 2025 |
| Lee Chan Henry | SVP, General Counsel | EXERCISE | $1M+ | 9K | $197.10 | Sep 12, 2025 |
| Lee Chan Henry | SVP, General Counsel | SELL | $1M+ | 10K | $325.53 | Sep 12, 2025 |
| Wang Lai | Global Head of R&D | SELL | $1M+ | 5K | $350.06 | Sep 11, 2025 |
| Sanders Corazon (Corsee) D. | Director | SELL | $500K+ | 3K | $337.00 | Sep 9, 2025 |
| Sanders Corazon (Corsee) D. | Director | EXERCISE | $100K–$500K | 3K | $155.68 | Sep 9, 2025 |
| Ball Titus B. | Principal Accounti… | SELL | $15K–$50K | 122 | $326.76 | Sep 4, 2025 |
| Wang Lai | Global Head of R&D | SELL | $1M+ | 4K | $302.65 | Jul 31, 2025 |
| Lee Chan Henry | SVP, General Counsel | SELL | $100K–$500K | 920 | $304.60 | Jul 31, 2025 |
| Wang Lai | Global Head of R&D | SELL | $100K–$500K | 700 | $300.00 | Jul 22, 2025 |
| OYLER JOHN | CEO | SELL | $1M+ | 28K | $253.38 | Jul 11, 2025 |
| Wang Lai | Global Head of R&D | SELL | $100K–$500K | 1K | $260.00 | Jun 25, 2025 |
| Wu Xiaobin | President and COO | SELL | $100K–$500K | 1K | $260.00 | Jun 25, 2025 |
| Wang Xiaodong | Director | SELL | $500K+ | 2K | $265.50 | Jun 25, 2025 |
| OYLER JOHN | CEO | SELL | $500K+ | 3K | $261.61 | Jun 25, 2025 |
| Lee Chan Henry | SVP, General Counsel | SELL | $100K–$500K | 422 | $266.50 | Jun 18, 2025 |
| Wang Lai | Global Head of R&D | SELL | $100K–$500K | 2K | $262.11 | Jun 18, 2025 |
| Wu Xiaobin | President and COO | SELL | $500K+ | 2K | $261.27 | Jun 18, 2025 |
| OYLER JOHN | CEO | SELL | $1M+ | 5K | $263.33 | Jun 18, 2025 |
| Ball Titus B. | Principal Accounti… | GRANT | N/A | 30K | — | Jun 12, 2025 |
| Ball Titus B. | Principal Accounti… | SELL | $15K–$50K | 134 | $258.36 | Jun 12, 2025 |
| Wang Xiaodong | Director | GRANT | N/A | 99K | — | Jun 12, 2025 |
| Wang Xiaodong | Director | EXERCISE | $100K–$500K | 42K | $6.50 | Jun 12, 2025 |
| Wang Xiaodong | Director | SELL | $1M+ | 42K | $262.82 | Jun 12, 2025 |
| Lee Chan Henry | SVP, General Counsel | SELL | $100K–$500K | 700 | $256.11 | Jun 10, 2025 |
| Wang Lai | Global Head of R&D | SELL | $100K–$500K | 1K | $252.39 | Jun 10, 2025 |
| Wu Xiaobin | President and COO | SELL | $100K–$500K | 2K | $253.15 | Jun 10, 2025 |
| OYLER JOHN | CEO | SELL | $1M+ | 5K | $252.77 | Jun 10, 2025 |
| BAKER BROS. ADVISORS LP | Director | SELL | $1M+ | 733K | $260.00 | Mar 1, 2025 |
🔓Seeing ranges? Sign in for exact trade values — free forever
Institutional Ownership
13F filings as of Dec 31, 2025 · 236 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| Capital International Investors | 5.1M | $1M+ | SH |
| PRIMECAP MANAGEMENT CO/CA/ | 5.0M | $1M+ | SH |
| HHLR ADVISORS, LTD. | 1.0M | $1M+ | SH |
| Siren, L.L.C. | 500K | $1M+ | SH |
| Capital International, Inc./CA/ | 308K | $1M+ | SH |
| Baird Financial Group, Inc. | 304K | $1M+ | SH |
| Man Group plc | 249K | $1M+ | SH |
| Candriam S.C.A. | 197K | $1M+ | SH |
| BNP PARIBAS FINANCIAL MARKETS | 194K | $1M+ | SH |
| Capital International Sarl | 153K | $1M+ | SH |
| M&G Plc | 130K | $1M+ | SH |
| FIRST TRUST ADVISORS LP | 126K | $1M+ | SH |
| Jain Global LLC | 97K | $1M+ | SH |
| VAN ECK ASSOCIATES CORP | 90K | $1M+ | SH |
| JENNISON ASSOCIATES LLC | 76K | $1M+ | SH |
| Patient Square Capital LP | 69K | $1M+ | SH |
| Squarepoint Ops LLC | 69K | $1M+ | SH |
| CAPITAL INTERNATIONAL LTD /CA/ | 68K | $1M+ | SH |
| ENVESTNET ASSET MANAGEMENT INC | 56K | $1M+ | SH |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 56K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13D/A · May 13, 2025
4.9%
68.6M shares
SC 13D/A · Mar 4, 2025
6.7%
92.8M shares
SC 13D/A · Dec 11, 2024
9.0%
124.8M shares
SC 13D/A · Dec 4, 2024
9.0%
125.0M shares
SC 13D/A · Nov 14, 2023
10.2%
138.2M shares
SC 13D/A · May 5, 2023
11.2%
152.5M shares
SC 13D/A · Feb 14, 2023
10.9%
147.0M shares
SC 13G/A · Feb 10, 2023
2.6%
35.7M shares
SC 13G/A · Feb 10, 2023
5.1%
70.0M shares
SC 13D/A · Aug 16, 2022
10.9%
147.0M shares
SC 13G/A · Feb 14, 2022
5.1%
69.6M shares
SC 13G · Feb 11, 2022
5.6%
39.0M shares
SC 13G/A · Feb 11, 2022
5.1%
69.6M shares